Effect of Selective Personality-Targeted Alcohol Use Prevention on 7-Year Alcohol-Related Outcomes Among High-risk Adolescents: A Secondary Analysis of a Cluster Randomized Clinical Trial.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 11 2022
Historique:
entrez: 17 11 2022
pubmed: 18 11 2022
medline: 22 11 2022
Statut: epublish

Résumé

Alcohol consumption is one of the leading preventable causes of burden of disease worldwide. Selective prevention of alcohol use can be effective in delaying the uptake and reducing harmful use of alcohol during the school years; however, little is known about the durability of these effects across the significant transition from early adolescence into late adolescence and early adulthood. To examine the sustained effects of a selective personality-targeted alcohol use prevention program on alcohol outcomes among adolescents who report high levels of 1 of 4 personality traits associated with substance use. A cluster randomized clinical trial was conducted to assess the effectiveness of the selective personality-targeted PreVenture program on reducing the growth of risky alcohol use and related harms from early to late adolescence and early adulthood. Participants included grade 8 students attending 14 secondary schools across New South Wales and Victoria, Australia, in 2012 who screened as having high levels of anxiety sensitivity, negative thinking, impulsivity, and/or sensation seeking. Schools were block randomized to either the PreVenture group (7 schools) or the control group (7 schools). The primary end point of the original trial was 2 years post baseline; the present study extends the follow-up period from July 1, 2017, to December 1, 2019, 7 years post baseline. Data were analyzed from July 22, 2021, to August 2, 2022. The PreVenture program is a 2-session, personality-targeted intervention designed to upskill adolescents to better cope with their emotions and behaviors. Self-reported monthly binge drinking, alcohol-related harms, and hazardous alcohol use measured by the Alcohol Use Disorders Identification Test-Concise consumption screener. Of 438 participants (249 male [56.8%]; mean [SD] age, 13.4 [0.5] years) from 14 schools, 377 (86.2%) provided follow-up data on at least 2 occasions, and among those eligible, 216 (54.0%) participated in the long-term follow-up. Compared with the control condition, the PreVenture intervention was associated with reduced odds of any alcohol-related harm (odds ratio [OR], 0.81 [95% CI, 0.70-0.94]) and a greater mean reduction in the frequency of alcohol-related harms (β = -0.22 [95% CI, -0.44 to -0.003]) at the 7.0-year follow-up. There were no differences in the odds of monthly binge drinking (OR, 0.80 [95% CI, 0.56-1.13]) or hazardous alcohol use (OR, 0.87 [95% CI, 0.59-1.27]) at the 7.0-year follow-up. Exploratory analyses at the 5.5-year follow-up showed that compared with the control condition, the PreVenture intervention was also associated with reduced odds of monthly binge drinking (OR, 0.87, [95% CI, 0.77-0.99]) and hazardous alcohol use (OR, 0.91 [95% CI, 0.84-0.99]), but this was not sustained. This study demonstrated that a brief selective personality-targeted alcohol use prevention intervention delivered in the middle school years can have sustained effects into early adulthood. anzctr.org.au Identifier: ACTRN12612000026820.

Identifiants

pubmed: 36394873
pii: 2798620
doi: 10.1001/jamanetworkopen.2022.42544
pmc: PMC9672969
doi:

Banques de données

ANZCTR
['ACTRN12612000026820']

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2242544

Références

Arch Intern Med. 1998 Sep 14;158(16):1789-95
pubmed: 9738608
Addiction. 2021 Mar;116(3):514-524
pubmed: 32621555
Cochrane Database Syst Rev. 2011 May 11;(5):CD009113
pubmed: 21563171
BMC Psychiatry. 2012 Aug 20;12:118
pubmed: 22906138
Pediatrics. 2020 Sep;146(3):
pubmed: 32769198
Addict Behav. 2016 Feb;53:23-30
pubmed: 26441044
Lancet. 2016 Jun 11;387(10036):2355-6
pubmed: 27174303
JMIR Res Protoc. 2018 Nov 06;7(11):e11372
pubmed: 30401663
Drug Alcohol Depend. 2018 Jul 1;188:266-273
pubmed: 29803033
Clin Psychol Rev. 2016 Mar;44:45-59
pubmed: 26722708
BMC Public Health. 2018 May 21;18(1):643
pubmed: 29783974
J Consult Clin Psychol. 2002 Dec;70(6):1207-23
pubmed: 12472298
J Am Acad Child Adolesc Psychiatry. 2001 Mar;40(3):265-73
pubmed: 11288767
Lancet Psychiatry. 2016 Mar;3(3):280-96
pubmed: 26905481
Addiction. 2015 Feb;110(2):269-78
pubmed: 25251778
Curr Addict Rep. 2016;3(4):426-436
pubmed: 27909645
Psychol Med. 2017 Oct;47(13):2246-2259
pubmed: 28399955
J Subst Abuse. 2001;13(4):493-504
pubmed: 11775078
Psychol Assess. 2012 Mar;24(1):21-35
pubmed: 21823800
Subst Abuse Treat Prev Policy. 2014 Dec 13;9:48
pubmed: 25495012
Addict Behav. 2009 Dec;34(12):1042-55
pubmed: 19683400
J Am Acad Child Adolesc Psychiatry. 2010 Sep;49(9):954-963.e1
pubmed: 20732631
PLoS Med. 2011 Feb 08;8(2):e1000413
pubmed: 21346802
J Child Psychol Psychiatry. 2008 Feb;49(2):181-90
pubmed: 18211277
Arch Gen Psychiatry. 2010 Jan;67(1):85-93
pubmed: 20048226
J Child Psychol Psychiatry. 2016 Sep;57(9):1056-65
pubmed: 27090500
J Paediatr Child Health. 2013 Nov;49(11):925-934
pubmed: 24251658
Lancet. 2018 Sep 22;392(10152):1015-1035
pubmed: 30146330
Addiction. 2004 Mar;99(3):278-91
pubmed: 14982537
Mol Psychiatry. 2022 Jan;27(1):281-295
pubmed: 34079068
J Stud Alcohol. 1989 Jan;50(1):30-7
pubmed: 2927120
J Am Acad Child Adolesc Psychiatry. 2022 Apr;61(4):520-532
pubmed: 34823025
Lancet Child Adolesc Health. 2018 Mar;2(3):223-228
pubmed: 30169257
Alcohol Res. 2021 Sep 09;41(1):11
pubmed: 34567915
Addiction. 2018 Oct;113(10):1811-1825
pubmed: 29749666
JAMA Psychiatry. 2013 Mar;70(3):334-42
pubmed: 23344135

Auteurs

Nicola C Newton (NC)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Jennifer Debenham (J)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Tim Slade (T)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Anna Smout (A)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Lucinda Grummitt (L)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Matthew Sunderland (M)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Emma L Barrett (EL)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Katrina E Champion (KE)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Cath Chapman (C)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Erin Kelly (E)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Siobhan Lawler (S)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Natalie Castellanos-Ryan (N)

Department of Psychiatry, University of Montreal, Montreal, Quebec, Canada.
Sainte Justine Hospital Research Centre, Montreal, Quebec, Canada.

Maree Teesson (M)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Patricia J Conrod (PJ)

Department of Psychiatry, University of Montreal, Montreal, Quebec, Canada.
Sainte Justine Hospital Research Centre, Montreal, Quebec, Canada.

Lexine Stapinski (L)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH